EGFR and non-small cell lung carcinoma: Small-molecule TKIs have been shown to have a high efficiency in patients with an exon 19 deletion in the EGFR gene (15); however, patients with NSCLC with EGFR mutations in exon 20 are resistant to drug treatment with TKIs (16).